Medical Equipment

Global Liver Cancer Diagnostics Market Expected to Reach $14.74 Billion by 2030 with 7.4% CAGR

March 13, 2026March 16, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Liver Cancer Diagnostics Market At The End Of The 2026–2030 Forecast Period?

The liver cancer diagnostics market has demonstrated substantial growth in recent years. Its valuation is set to rise from $10.32 billion in 2025 to $11.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be attributed to the escalating prevalence of chronic liver diseases, a growing incidence of hepatocellular carcinoma, the continuous expansion of hospital diagnostic infrastructure, increased awareness regarding early cancer screening, and notable advancements in both imaging and pathology techniques.

The liver cancer diagnostics market size is anticipated to experience significant expansion in the coming years. Its value is projected to reach $14.75 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This expansion during the forecast period is propelled by factors such as the greater acceptance of precision oncology diagnostics, an increasing need for non-invasive diagnostic approaches, the broadened scope of molecular testing capabilities, escalating financial commitments in oncology research, and the expanding deployment of AI-assisted diagnostic platforms. Key developments expected within this period involve the rising uptake of sophisticated molecular diagnostic examinations, a greater utilization of imaging-based instruments for early detection, the growing incorporation of biomarker-based screening protocols, the wider availability of personalized oncology diagnostics, and an intensified focus on identifying cancer at early stages.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp

What Drivers Are Shaping The Future Growth Of The Liver Cancer Diagnostics Market?

The increasing incidence of liver cancer is anticipated to drive expansion in the liver cancer diagnostics market in the future. This life-threatening illness is characterized by the uncontrolled growth and multiplication of liver cells. Diagnostic tests for liver cancer are crucial for determining the spread of malignant cells within or around the liver following an initial diagnosis of primary liver carcinoma, a necessity that, combined with the escalating number of cases, is consequently boosting the liver cancer diagnostics market. For example, in January 2023, data from the Cancer Facts & Figures 2023 report, issued by the American Cancer Society, a US-based voluntary health organization, indicated that new cases of liver and intrahepatic bile duct cancer among US females totaled 13,230 in 2023. Additionally, in 2023, an approximate 41,210 new liver cancer diagnoses were made in the US, with an anticipated 29,380 fatalities. Consequently, the escalating prevalence of liver cancer is a significant factor propelling the expansion of the liver cancer diagnostic market.

What Segment Types Make Up The Liver Cancer Diagnostics Market?

The liver cancer diagnostics market covered in this report is segmented –

1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma

2) By Screening: Laboratory Testing, Imaging, Biopsy, Other Screenings

3) By Technology: Fluorescent In Situ Hybridization (FISH), Immunohistochemical (IHC), Other Technologies

4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes

Subsegments:

1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma, Advanced-Stage Hepatocellular Carcinoma

2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma

3) By Hepatoblastoma: Pure Hepatoblastoma, Mixed Hepatoblastoma

Which Market Trends Are Creating New Opportunities In The Liver Cancer Diagnostics Market?

Leading firms within the liver cancer diagnostics market are focusing on creating sophisticated biomarker-based assays and algorithms, aiming to enhance the precision of diagnoses and facilitate prompt identification of the disease. These biomarker-based assays and algorithms represent diagnostic instruments that leverage distinct biological indicators for disease identification, thereby offering more accurate and streamlined diagnostic potential. A notable example is Roche Diagnostics, a US-based biotech corporation, which introduced the Elecsys PIVKA-II assay and Elecsys GAAD algorithm in November 2023. The Elecsys PIVKA-II assay is designed to identify increased levels of the PIVKA-II biomarker, a marker linked to hepatocellular carcinoma (HCC), thus improving the early discovery of liver cancer among individuals at elevated risk. Concurrently, the Elecsys GAAD algorithm combines several diagnostic indicators, including PIVKA-II and AFP, to boost diagnostic accuracy and simplify the process of making decisions related to liver cancer detection.

Who Are The Key Players Driving Competition In The Liver Cancer Diagnostics Market?

Major companies operating in the liver cancer diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc, Siemens Healthineers, Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon AS, BioGenex Laboratories Inc, OncoCyte Corporation, Guardant Health Inc, Exact Sciences Corporation, Grail Inc, Freenome Holdings Inc, Natera Inc, Personal Genome Diagnostics Inc, Thrive Earlier Detection Corp

Read the full liver cancer diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Which Geographic Regions Are Influencing Demand In The Liver Cancer Diagnostics Market?

North America was the largest region in the liver cancer diagnostics market in 2025. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liver Cancer Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10481&type=smp

Browse Through More Reports Similar to the Global Liver Cancer Diagnostics Market 2026, By The Business Research Company

Liver Health Supplements Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Unresectable Hepatocellular Carcinoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/unresectable-hepatocellular-carcinoma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795